[Artículo traducido] Alteraciones analíticas durante el tratamiento con dupilumab para la dermatitis atópica
Resumen: Introducción: Dupilumab es un anticuerpo monoclonal inhibidor de la IL-4/IL-13 aprobado para el tratamiento de la dermatitis atópica (DA) con perfiles de eficacia y seguridad notables. Sin embargo, estudios previos han informado de un aumento de los eosinófilos séricos durante el tratamien...
Saved in:
| Main Authors: | D. Flor, C. Montero-Vilchez, T. Montero-Vilchez, S. Arias-Santiago, M. Gonçalo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Actas Dermo-Sifiliográficas |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0001731025001024 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Laboratory Changes During Dupilumab Treatment for Atopic Dermatitis
by: D. Flor, et al.
Published: (2025-05-01) -
T cell immunophenotypes and IgE responses in patients with moderate‐to‐severe atopic dermatitis receiving dupilumab
by: Davender Redhu, et al.
Published: (2025-05-01) -
Modern Possibilities of Usage Dupilumab in Children
by: Anna A. Kosova, et al.
Published: (2024-12-01) -
High Prevalence of Lash Collarettes in Patients with Atopic Dermatitis Treated with Dupilumab
by: Ilaria Trave, et al.
Published: (2025-08-01) -
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01)